Physician profile
Anne Mian
NPI 1518910835
$3,115.76
in general payments reported to CMS, 2019-2025
29 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $436 · 2021: $827 · 2022: $512 · 2023: $172 · 2024: $452 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745 · Education: $39.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.45 |
| Education | $39.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $837.21 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $326.04 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $317.55 | 2019-2022 | |
| Alkermes, INC. | $262.74 | 2019-2023 | Lybalvi |
| Otsuka America Pharmaceutical, INC. | $190.82 | 2019-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $125.58 | 2019-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $123.58 | 2020-2024 | Trintellix |
| Lundbeck LLC | $111.54 | 2019-2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $111.32 | 2019-2021 | |
| Allergan, INC. | $109.97 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $72.35 | 2019-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $69.56 | 2019-2024 | Austedo Xr |
| Jazz Pharmaceuticals INC. | $61.51 | 2020-2021 | |
| Neos Therapeutics, LP | $48.31 | 2019-2025 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $36.41 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $34.95 | 2019 | |
| Validus Pharmaceuticals LLC | $32.82 | 2019-2025 | Equetro, Raldesy |
| Bausch Health US, LLC | $29.02 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
| Arbor Pharmaceuticals, INC. | $26.15 | 2019 | |
| Alfasigma USA, INC. | $25.26 | 2021 | |
| Shire North American Group INC | $24.81 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.60 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $18.75 | 2024 | Qelbree |
| Avanir Pharmaceuticals, INC. | $15.41 | 2019 | |
| Almatica Pharma LLC | $15.22 | 2021 | |
| Axsome Therapeutics, INC. | $14.30 | 2024 | Sunosi |
| Noven Therapeutics, LLC | $12.61 | 2022 | |
| Merck Sharp & Dohme LLC | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Mian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.